Reuters logo
BRIEF-Keytruda approved in japan for first-line treatment of patients with advanced non-small cell lung cancer
December 19, 2016 / 12:27 PM / 9 months ago

BRIEF-Keytruda approved in japan for first-line treatment of patients with advanced non-small cell lung cancer

Dec 19 (Reuters) - Merck & Co Inc -

* Keytruda (pembrolizumab) approved as first anti-pd-1 therapy in Japan for first-line treatment of patients with advanced non-small cell lung cancer (nsclc) whose tumors express high levels of PD-l1

* Keytruda also approved for second-line treatment of patients with advanced NSCLC whose tumors express PD-l1 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below